Urgent therapy for stroke: Part I. Pilot study of tissue plasminogen activator administered within 90 minutes

Thomas G Brott, E. Clarke Haley, David E. Levy, William Barsan, Joseph Broderick, George L. Sheppard, Judith Spilker, Gail L. Kongable, Sandra Massey, Robert Reed, John R. Marler

Research output: Contribution to journalArticle

423 Citations (Scopus)

Abstract

Background and Purpose: Thrombolytic agents hold theoretical promise as therapy for cerebral infarction. This study was designed to evaluate the safety of tissue plasminogen activator, to accomplish urgent patient treatment, and to estimate potential efficacy of tissue plasminogen activator. Methods: Following neurological evaluation and computed tomography of the brain, patients with acute ischemic stroke were evaluated and treated with intravenous tissue plasminogen activator under an open-label, dose-escalation design within 90 minutes from symptom onset. End points examined included symptomatic and asymptomatic intracranial hematoma, systemic hemorrhage, and neurological outcome at 2 hours, 24 hours, and 3 months. Results: Seventy-four patients were treated within 90 minutes of symptom onset over seven dose tiers of tissue plasminogen activator, ranging from 0.35 mg/kg to 1.08 mg/kg. Intracranial hematoma with associated neurological deterioration occurred in three patients and was related to increasing doses of tissue plasminogen activator (p=0.045). Intracranial hematoma did not occur in any of the 58 patients treated with ≤0.85 mg/kg. Major neurological improvement occurred in 22 patients (30%) at 2 hours from the initiation of tissue plasminogen activator and in a total of 34 patients (46%) at 24 hours, but major neurological improvement was not related to increasing doses of tissue plasminogen activator or to stroke type. Conclusions: Patients with acute stroke can be evaluated and treated within 90 minutes. Tissue plasminogen activator for acute ischemic infarction is not without risk, but the potential for clinical benefit justifies a randomized clinical trial. To date, differences in hemorrhagic risk or neurological benefit of tissue plasminogen activator for particular ischemic stroke types are not apparent.

Original languageEnglish (US)
Pages (from-to)632-640
Number of pages9
JournalStroke
Volume23
Issue number5
StatePublished - May 1992
Externally publishedYes

Fingerprint

Tissue Plasminogen Activator
Stroke
Hematoma
Therapeutics
Fibrinolytic Agents
Cerebral Infarction
Infarction
Randomized Controlled Trials
Tomography
Hemorrhage
Safety
Brain

Keywords

  • Cerebral ischemia
  • Plasminogen activator, tissue-type
  • Thrombolytic therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

Brott, T. G., Haley, E. C., Levy, D. E., Barsan, W., Broderick, J., Sheppard, G. L., ... Marler, J. R. (1992). Urgent therapy for stroke: Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke, 23(5), 632-640.

Urgent therapy for stroke : Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. / Brott, Thomas G; Haley, E. Clarke; Levy, David E.; Barsan, William; Broderick, Joseph; Sheppard, George L.; Spilker, Judith; Kongable, Gail L.; Massey, Sandra; Reed, Robert; Marler, John R.

In: Stroke, Vol. 23, No. 5, 05.1992, p. 632-640.

Research output: Contribution to journalArticle

Brott, TG, Haley, EC, Levy, DE, Barsan, W, Broderick, J, Sheppard, GL, Spilker, J, Kongable, GL, Massey, S, Reed, R & Marler, JR 1992, 'Urgent therapy for stroke: Part I. Pilot study of tissue plasminogen activator administered within 90 minutes', Stroke, vol. 23, no. 5, pp. 632-640.
Brott TG, Haley EC, Levy DE, Barsan W, Broderick J, Sheppard GL et al. Urgent therapy for stroke: Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992 May;23(5):632-640.
Brott, Thomas G ; Haley, E. Clarke ; Levy, David E. ; Barsan, William ; Broderick, Joseph ; Sheppard, George L. ; Spilker, Judith ; Kongable, Gail L. ; Massey, Sandra ; Reed, Robert ; Marler, John R. / Urgent therapy for stroke : Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. In: Stroke. 1992 ; Vol. 23, No. 5. pp. 632-640.
@article{0f4b55aeb234400a84dcce36fd0bb85b,
title = "Urgent therapy for stroke: Part I. Pilot study of tissue plasminogen activator administered within 90 minutes",
abstract = "Background and Purpose: Thrombolytic agents hold theoretical promise as therapy for cerebral infarction. This study was designed to evaluate the safety of tissue plasminogen activator, to accomplish urgent patient treatment, and to estimate potential efficacy of tissue plasminogen activator. Methods: Following neurological evaluation and computed tomography of the brain, patients with acute ischemic stroke were evaluated and treated with intravenous tissue plasminogen activator under an open-label, dose-escalation design within 90 minutes from symptom onset. End points examined included symptomatic and asymptomatic intracranial hematoma, systemic hemorrhage, and neurological outcome at 2 hours, 24 hours, and 3 months. Results: Seventy-four patients were treated within 90 minutes of symptom onset over seven dose tiers of tissue plasminogen activator, ranging from 0.35 mg/kg to 1.08 mg/kg. Intracranial hematoma with associated neurological deterioration occurred in three patients and was related to increasing doses of tissue plasminogen activator (p=0.045). Intracranial hematoma did not occur in any of the 58 patients treated with ≤0.85 mg/kg. Major neurological improvement occurred in 22 patients (30{\%}) at 2 hours from the initiation of tissue plasminogen activator and in a total of 34 patients (46{\%}) at 24 hours, but major neurological improvement was not related to increasing doses of tissue plasminogen activator or to stroke type. Conclusions: Patients with acute stroke can be evaluated and treated within 90 minutes. Tissue plasminogen activator for acute ischemic infarction is not without risk, but the potential for clinical benefit justifies a randomized clinical trial. To date, differences in hemorrhagic risk or neurological benefit of tissue plasminogen activator for particular ischemic stroke types are not apparent.",
keywords = "Cerebral ischemia, Plasminogen activator, tissue-type, Thrombolytic therapy",
author = "Brott, {Thomas G} and Haley, {E. Clarke} and Levy, {David E.} and William Barsan and Joseph Broderick and Sheppard, {George L.} and Judith Spilker and Kongable, {Gail L.} and Sandra Massey and Robert Reed and Marler, {John R.}",
year = "1992",
month = "5",
language = "English (US)",
volume = "23",
pages = "632--640",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Urgent therapy for stroke

T2 - Part I. Pilot study of tissue plasminogen activator administered within 90 minutes

AU - Brott, Thomas G

AU - Haley, E. Clarke

AU - Levy, David E.

AU - Barsan, William

AU - Broderick, Joseph

AU - Sheppard, George L.

AU - Spilker, Judith

AU - Kongable, Gail L.

AU - Massey, Sandra

AU - Reed, Robert

AU - Marler, John R.

PY - 1992/5

Y1 - 1992/5

N2 - Background and Purpose: Thrombolytic agents hold theoretical promise as therapy for cerebral infarction. This study was designed to evaluate the safety of tissue plasminogen activator, to accomplish urgent patient treatment, and to estimate potential efficacy of tissue plasminogen activator. Methods: Following neurological evaluation and computed tomography of the brain, patients with acute ischemic stroke were evaluated and treated with intravenous tissue plasminogen activator under an open-label, dose-escalation design within 90 minutes from symptom onset. End points examined included symptomatic and asymptomatic intracranial hematoma, systemic hemorrhage, and neurological outcome at 2 hours, 24 hours, and 3 months. Results: Seventy-four patients were treated within 90 minutes of symptom onset over seven dose tiers of tissue plasminogen activator, ranging from 0.35 mg/kg to 1.08 mg/kg. Intracranial hematoma with associated neurological deterioration occurred in three patients and was related to increasing doses of tissue plasminogen activator (p=0.045). Intracranial hematoma did not occur in any of the 58 patients treated with ≤0.85 mg/kg. Major neurological improvement occurred in 22 patients (30%) at 2 hours from the initiation of tissue plasminogen activator and in a total of 34 patients (46%) at 24 hours, but major neurological improvement was not related to increasing doses of tissue plasminogen activator or to stroke type. Conclusions: Patients with acute stroke can be evaluated and treated within 90 minutes. Tissue plasminogen activator for acute ischemic infarction is not without risk, but the potential for clinical benefit justifies a randomized clinical trial. To date, differences in hemorrhagic risk or neurological benefit of tissue plasminogen activator for particular ischemic stroke types are not apparent.

AB - Background and Purpose: Thrombolytic agents hold theoretical promise as therapy for cerebral infarction. This study was designed to evaluate the safety of tissue plasminogen activator, to accomplish urgent patient treatment, and to estimate potential efficacy of tissue plasminogen activator. Methods: Following neurological evaluation and computed tomography of the brain, patients with acute ischemic stroke were evaluated and treated with intravenous tissue plasminogen activator under an open-label, dose-escalation design within 90 minutes from symptom onset. End points examined included symptomatic and asymptomatic intracranial hematoma, systemic hemorrhage, and neurological outcome at 2 hours, 24 hours, and 3 months. Results: Seventy-four patients were treated within 90 minutes of symptom onset over seven dose tiers of tissue plasminogen activator, ranging from 0.35 mg/kg to 1.08 mg/kg. Intracranial hematoma with associated neurological deterioration occurred in three patients and was related to increasing doses of tissue plasminogen activator (p=0.045). Intracranial hematoma did not occur in any of the 58 patients treated with ≤0.85 mg/kg. Major neurological improvement occurred in 22 patients (30%) at 2 hours from the initiation of tissue plasminogen activator and in a total of 34 patients (46%) at 24 hours, but major neurological improvement was not related to increasing doses of tissue plasminogen activator or to stroke type. Conclusions: Patients with acute stroke can be evaluated and treated within 90 minutes. Tissue plasminogen activator for acute ischemic infarction is not without risk, but the potential for clinical benefit justifies a randomized clinical trial. To date, differences in hemorrhagic risk or neurological benefit of tissue plasminogen activator for particular ischemic stroke types are not apparent.

KW - Cerebral ischemia

KW - Plasminogen activator, tissue-type

KW - Thrombolytic therapy

UR - http://www.scopus.com/inward/record.url?scp=0026742376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026742376&partnerID=8YFLogxK

M3 - Article

C2 - 1579958

AN - SCOPUS:0026742376

VL - 23

SP - 632

EP - 640

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 5

ER -